Life sciences business secures NHS distribution for new product

University of Leeds spin out, Tissue Regenix has entered into a distribution agreement and secured its first order with a speciality supplier for the UK distribution of OrthoPure® XT, following its recent CE Mark approval in June.

Under the terms of the agreement, the NHS and private healthcare sectors will have access to the product which utilises the life sciences business’ patented dCELL® technology and via reconstruction of knee ligaments restores knee function and stability.

Tissue Regenix has said it will initially focus on commercialisation of OrthoPure® XT in the UK before commencing a gradual roll-out into certain other European countries over time.

The first order has already been received and delivery is expected to take place during Q4 2020, with demand for this product line expected to increase in 2021 as additional distribution opportunities are identified.

Gareth Jones, interim chief executive officer at Tissue Regenix said, “As a specialist supplier of orthopaedic and biologic products to the NHS, we have secured an ideal partner to support the commercialisation of OrthoPure® XT in the UK. We believe OrthoPure® XT has the potential to be a disruptive product in the market for reconstruction of knee ligaments and offers benefits to patients and healthcare providers. The launch of OrthoPure® XT is a key milestone for the Company as we continue to strengthen our product portfolio.”